Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)

被引：0
|
作者：
Zheng, Jenny
Yu, Yanke
Durairaj, Chandrasekar
Amantea, Michael
Dieras, Veronique
Finn, Richard
Wang, Diane
机构：
[1] Pfizer, San Diego, CA USA
[2] Inst Curie, Paris, France
[3] Ctr Eugene Marquis, Rennes, France
[4] Univ Calif Los Angeles, Geffen Sch Med, Santa Monica, CA USA
[5] Pfizer, Clin Pharmacol, San Diego, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-21
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
    Campone, M.
    De laurentiis, M.
    Zamagni, C.
    Kudryavcev, I.
    Agterof, M.
    Brown-Glaberman, U.
    Palacova, M.
    Chatterjee, S.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Martin, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC) participating in the PALOMA trials
    Isaacs, Claudine
    Mahtani, Reshma
    Lynce, Filipa
    Sleckman, Bethany
    Castrellon, Aurelio
    Kalmadi, Sujith
    Theall, Kathy Puyana
    Huang, Xin
    Bananis, Eustratios
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in real-world settings
    Rocque, Gabrielle Betty
    Blum, Joanne Lorraine
    Ji, Yan
    Pluard, Timothy J.
    Migas, John
    Lakhanpal, Shailendra
    Jepsen, Erin Stephany
    Wang, Yao
    Montelongo, Monica Z.
    Zhang, Zhe
    Gauthier, Eric Roland
    Tripathy, Debashish
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Characterization of neutropenia in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS
    Tripathy, Debu
    Blum, Joanne L.
    Sleckman, Bethany
    Patel, Kamal
    Nakhoul, Ibrahim
    Gauthier, Eric
    Montelongo, Monica Z.
    Zhang, Zhe
    Wang, Yao
    Rocque, Gabrielle B.
    CANCER RESEARCH, 2023, 83 (05)
  • [36] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [37] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
    Swallow, Elyse
    Wang, Jenny
    Thomason, Darren
    Tan, Ruo-Ding
    Kageleiry, Andrew
    Signorovitch, James
    CANCER RESEARCH, 2015, 75
  • [38] The real-world Hellenic disease management patterns with everolimus (EVE) for women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (aBC): 'The MIRROR' study
    Zagouri, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S370 - S370
  • [39] COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S39 - S39
  • [40] PALBOCICLIB DOSING, WASTAGE AND COSTS AMONG POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR/HER2-) METASTATIC BREAST CANCER (MBC): A CLAIMS ANALYSIS
    Princic, N.
    Brouillette, M.
    Tang, D.
    Lanoue, B.
    Barghout, V
    VALUE IN HEALTH, 2017, 20 (05) : A105 - A105
12345